Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 5/20 | 0.49 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | VNN1 | O95497 | 2/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6468178 | 0.88 | DPP4 (0.47) | DPP4VNN1ATML3MBTL1POLB | |
| SCHEMBL5131614 | 0.86 | OPRK1 (0.53) | DPP4KMT2AVNN1OPRM1OPRD1 | |
| SCHEMBL6470735 | 0.86 | VNN1 (0.43) | DPP4KMT2AVNN1OPRM1OPRD1 | |
| SCHEMBL6471110 | 0.85 | DPP4 (0.53) | DPP4VNN1OPRM1OPRD1OPRK1 | |
| SCHEMBL6471055 | 0.83 | MAOB (0.47) | DPP4SCN9AKMT2AOPRM1OPRD1 | |
| SCHEMBL6469203 | 0.82 | BCHE (0.41) | DPP4SCN9AKMT2AOPRK1MEN1 | |
| SCHEMBL5133518 | 0.81 | DPP4 (0.44) | DPP4KMT2AVNN1OPRM1OPRD1 | |
| SCHEMBL28344616 | 0.81 | NR3C2 (0.51) | SCN9AKMT2AVNN1OPRM1OPRD1 | |
| SCHEMBL6469026 | 0.81 | DPP4 (0.53) | DPP4VNN1OPRM1OPRD1OPRK1 | |
| SCHEMBL5042774 | 0.80 | TMEM97 (0.57) | DPP4KMT2AVNN1OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050107381-A1 | 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders | PFIZER, INC. | 2005-05-19 | — | — | US | claimed |
| US-20050107381-A1 | 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders | PFIZER, INC. | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107381-A1 | 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders | APP, BACE1, SNCA | DPP4 3527/4885SCN9A 666/4885KMT2A 2085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.